Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and leucine

rosiglitazone has been researched along with leucine in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Auwerx, J; Bac, P; Blanchard, SG; Champy, MF; Desreumaux, P; Dubuquoy, L; Gelman, L; Leesnitzer, LM; Moras, D; Picard, F; Plunket, KD; Potier, N; Renaud, JP; Rocchi, S; Vamecq, J; Zeyer, D1
Agostini, M; Chatterjee, VK; Garnes, KT; Gurnell, M; Levinson, SH; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schwabe, JW; Smith, AG; Willson, TM; Wood, EM; Xu, HE1
Amiri, F; Benkirane, K; Diep, QN; El Mabrouk, M; Schiffrin, EL1

Other Studies

4 other study(ies) available for rosiglitazone and leucine

ArticleYear
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
    Molecular cell, 2001, Volume: 8, Issue:4

    Topics: Adipocytes; Amino Acids; Animals; Binding Sites; Blood Glucose; Body Weight; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Fluorenes; Gene Expression Regulation; Genes, Reporter; Hypoglycemic Agents; Insulin Resistance; Leucine; Ligands; Male; Mice; Mice, Inbred Strains; Molecular Structure; Protein Binding; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tyrosine

2001
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
    Endocrinology, 2004, Volume: 145, Issue:4

    Topics: Amino Acid Sequence; Cell Line; Gene Expression; Genes, Dominant; Humans; Leucine; Ligands; Methionine; Models, Structural; Molecular Sequence Data; Monocytes; Mutation; Oxazoles; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine; Valine

2004
PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1.
    American journal of physiology. Heart and circulatory physiology, 2006, Volume: 290, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Carrier Proteins; Cell Proliferation; Intracellular Signaling Peptides and Proteins; Leucine; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoproteins; Phosphoric Monoester Hydrolases; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Rosiglitazone; Signal Transduction; Thiazolidinediones; Thymidine

2006